ClinicalTrials.gg
CompletedNCT05858788Updated Sep 18, 2025

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

A Phase 1 interventional study of SAR441566 in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Arthritis, Rheumatoid by Sanofi — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Sanofi.

Enrollment
34th of 34
10 · median 108
Started
2023
with 2 others
Phase 1
9 of 36
1 open now
Registered
31st of 36
by date

Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is the 34th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2023, is one of 9 in phase 1, and was the 31st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 36 studies in Arthritis, Rheumatoid by Sanofi are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Arthritis, Rheumatoid by Sanofi, or all of them as a file.
02

Study summary

This is a cross-over, Phase 1, 3-treatment period single sequence study. The purpose of this study is to characterize pharmacokinetics (PK), safety, and tolerability of single ascending oral doses of SAR441566 in healthy male Japanese participants, 18-55 years of age.

Read the detailed description

The duration of the study for a participant will be up to approximately 65 days.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese participants whose Japanese ethnicity is defined according to the following criteria: born in Japan or born outside of Japan, and are descendent of 4 ethnic Japanese grandparents who were all born in Japan.
  • Male participants between the ages of 18 and 55 years, inclusive
  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination including 12-lead , and clinical laboratory tests)
  • Body weight between 50.0 and 100.0 kg, inclusive, and (BMI) between 18.0 and 30.0 kg/m\^2, inclusive.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, dermatological (including phototoxic dermatitis), osteomuscular, articular, psychiatric, systemic, ocular, immune disorders or infectious disease, or signs of acute illness.
  • Receipt of live (attenuated) vaccines within 3 months and/or non (eg, COVID-19 vaccination) within 4 weeks prior to first dose on Day 1, or planned to receive these vaccines at any time throughout the study.
  • History of tuberculosis and/or a positive QuantiFERON-TB Gold (QFT) test.
  • Positive result on any of the following tests: surface (HBs Ag) antigen, anti-hepatitis B core antibody (anti-HBc Ab), anti- virus antibody (anti-HCV Ab), anti- 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab), SARS-CoV-2
  • Any medication within 14 days before inclusion (before first study treatment administration) or within 5 times the elimination half-life or pharmacodynamic half-life of the medication whichever the longest.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    SAR441566

    Participants will receive single ascending doses of SAR441566 on day 1 of each 8-12-day cycle

    Drug: SAR441566

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: Cmax

    Maximum plasma concentration observed

    Time frame: From Day 1 to Day 5 of each period (5 days per period)

  2. Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: AUClast

    Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time Tlast (AUClast)

    Time frame: From Day 1 to Day 5 of each period (5 days per period)

  3. Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: AUC

    Area under the plasma concentration versus time curve extrapolated to infinity (AUC)

    Time frame: From Day 1 to Day 5 of each period (5 days per period)

Secondary outcomes

  1. Number of participants with adverse events (AE) and treatment-emergent adverse events (TEAEs)

    Assessment of adverse events (AE) / treatment-emergent adverse events (TEAE) including Serious AE and AE of Special Interest

    Time frame: Up to end of study visit (which will occur at latest day 37 of study)

07

Study locations

1 site
  • Parexel International-Site Number:8400001
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jul 2023, 2 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 2 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2023
First posted
May 15, 2023
StartActual
May 15, 2023
Primary completionActual
Jul 17, 2023
CompletionActual
Jul 17, 2023
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05858788
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 15, 2023
Start date
May 15, 2023
Primary completion
Jul 17, 2023
Completion
Jul 17, 2023
Last update
Sep 18, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Balinatunfib

Start the discussion